Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 3,455 matching trials from the live ClinicalTrials.gov search.
Conditions
Osteoarthritis, Knee
Interventions
Ibuprofen, celecoxib, placebo
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
33
States / cities
Anniston, Alabama • Phoenix, Arizona • Anaheim, California + 30 more
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 74 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
47
States / cities
Birmingham, Alabama • Beverly Hills, California • Encino, California + 40 more
Conditions
Painful Diabetic Neuropathy
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Narcolepsy Type 1
Interventions
Oveporexton, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
16 Years to 70 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Phoenix, Arizona • Redwood City, California • Santa Ana, California + 12 more
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications

NCT04885530
Conditions
Covid19
Interventions
Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
10,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
110
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
Conditions
Non Small Cell Lung Cancer (Stage III)
Interventions
Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
5
States / cities
Duarte, California • Atlanta, Georgia • Florham Park, New Jersey + 2 more
Conditions
Autism Spectrum Disorder
Interventions
ML-004 (IR)/(ER) tablet, ML-004 Placebo
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
12 Years to 45 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Dothan, Alabama • Phoenix, Arizona • Glendale, California + 21 more
Terminated Phase 2 Interventional Results available

Fasiglifam 25 mg BID vs 50 mg QD

NCT01982253
Conditions
Type 2 Diabetes Mellitus
Interventions
Fasiglifam, Placebo to fasiglifam
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
47
States / cities
Goodyear, Arizona • Long Beach, California • Los Angeles, California + 44 more
Conditions
Healthy Participants Study
Interventions
KT-621, Placebo
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Phoenix, Arizona • Lincoln, Nebraska
Conditions
Endometriosis
Interventions
Vilaprisan (BAY1002670), Matching Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Boynton Beach, Florida • Jacksonville, Florida + 3 more
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
Macitentan, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 80 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
24
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 20 more
Completed Not applicable Interventional Accepts healthy volunteers

Isoleucine Intake and Intermediary Metabolism in Type 2 Diabetes

NCT04461236
Conditions
Type 2 Diabetes
Interventions
Oral Supplement, Placebo
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 84 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
College Station, Texas
Conditions
Bullous Pemphigoid
Interventions
nomacopan (rVA576), Placebo
Drug · Other
Lead sponsor
AKARI Therapeutics
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Los Angeles, California • Skokie, Illinois • Indianapolis, Indiana + 4 more
Conditions
Major Depressive Disorder
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
53
States / cities
Rogers, Arkansas • Bellflower, California • Garden Grove, California + 44 more
Terminated Phase 4 Interventional Results available

Naltrexone/Bupropion Cardiovascular Outcomes Study

NCT02638129
Conditions
Obesity, Cardiovascular Diseases
Interventions
Naltrexone HCl/Bupropion HCl ER, Placebo
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
139
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)

NCT00862745
Conditions
Urge Urinary Incontinence, Overactive Bladder
Interventions
Fesoterodine, Matching Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
645 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more
Completed Phase 2 Interventional Results available

LIPS-A: Lung Injury Prevention Study With Aspirin

NCT01504867
Conditions
Acute Respiratory Distress Syndrome
Interventions
Aspirin, Lactose powder
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
16
States / cities
Stanford, California • Bridgeport, Connecticut • Gainsville, Florida + 11 more
Conditions
Venous Leg Ulcer
Interventions
S42909 100 mg, S42909 200 mg, S42909 400 mg, S42909 800 mg, S42909 1200 mg, Placebo Oral Tablet
Drug
Lead sponsor
Ilkos Therapeutic Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Carlsbad, California • Carmichael, California • Castro Valley, California + 10 more
Conditions
Hypercholesterolaemia
Interventions
Laroprovstat, Rosuvastatin 1, Rosuvastatin 2, Laroprovstat/Rosuvastatin 1, Placebo to match rosuvastatin, Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1, Laroprovstat/Rosuvastatin 2, Placebo to match Laroprovstat/Rosuvastatin 2
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
77
States / cities
Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 69 more
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and current lipid-lowering treatment, Current lipid-lowering treatment
Drug
Lead sponsor
Takeda
Industry
Eligibility
8 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Cincinnati, Ohio • Columbus, Ohio
Conditions
Chronic Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
55 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
72
States / cities
Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 69 more
Conditions
Epilepsy With Partial-onset Seizures
Interventions
Lacosamide, Placebo
Drug · Other
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
1 Month to 47 Months
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Tampa, Florida • Henderson, Nevada + 3 more
Conditions
Psoriatic Arthritis
Interventions
Filgotinib, Placebo to match filgotinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
22
States / cities
Covina, California • DeBary, Florida • Miami, Florida + 19 more